# New Chemicals That Block Specific Adenosine Receptors for Treating Diseases

> This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases.

- **Patent:** US 12735424
- **Original title:** Fused pyrazine derivatives as A2A / A2B inhibitors
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** pharmaceutical, biotech, cancer, inflammatory_diseases, cardiovascular, neurodegenerative_diseases

## What it does

This patent application introduces a group of new chemical compounds, referred to as "compounds of Formula (I)," or their "pharmaceutically acceptable salts." These compounds are designed to change how adenosine receptors, specifically the A2A and A2B subtypes, work in the body. By blocking or reducing the activity of these receptors, the compounds aim to be useful in treating various diseases. For example, they could potentially be used to treat certain types of cancer, reduce inflammation, manage cardiovascular problems, or address neurodegenerative conditions.

## What it does NOT cover

- Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.
- Does not cover compounds that activate A2A or A2B receptors, as the focus is on 'inhibitors' or 'modulators' for treatment.
- Does not cover compounds that exclusively target other adenosine receptor subtypes like A1 or A3, or entirely different types of receptors.
- Does not cover methods of diagnosing diseases using these compounds, only their use in the 'treatment of diseases'.
- Does not cover the treatment of diseases that are not related to the activity of adenosine receptors.

## The clever bit

The innovation lies in discovering specific 'fused pyrazine derivatives' with a unique chemical structure (Formula I) that effectively and selectively block A2A and A2B adenosine receptors. This precision in targeting these receptors with a novel compound class offers a new pathway for developing treatments for complex diseases.

## Real-world examples

1. Drugs targeting A2A receptors in oncology
2. Anti-inflammatory medications
3. Treatments for certain cardiovascular diseases
4. Therapies for neurodegenerative disorders

## Why it matters

Adenosine receptors, particularly A2A and A2B, play significant roles in many biological processes, including immune responses, inflammation, and heart function. Modulating these receptors is a key strategy in drug development for various serious conditions. This patent aims to provide new chemical tools that could lead to novel drug candidates for major diseases like cancer, where A2A receptor blockade is a known approach to enhance anti-tumor immunity.

## Frequently asked questions

### What does New Chemicals That Block Specific Adenosine Receptors for Treating Diseases cover?

This patent describes new chemical compounds, called fused pyrazine derivatives, designed to block specific adenosine receptors (A2A and A2B) in the body, which could help treat conditions like cancer, inflammatory, cardiovascular, and neurodegenerative diseases.

### When does this patent expire?

This patent is expected to expire on September 15, 2046, when the invention enters the public domain.

### What problem does this patent solve?

Adenosine receptors, particularly A2A and A2B, play significant roles in many biological processes, including immune responses, inflammation, and heart function. Modulating these receptors is a key strategy in drug development for various serious conditions. This patent aims to provide new chemical tools that could lead to novel drug candidates for major diseases like cancer, where A2A receptor blockade is a known approach to enhance anti-tumor immunity.

### What does this patent NOT cover?

Does not cover chemical compounds that are not 'fused pyrazine derivatives' or do not fit the specific 'Formula (I)' structure.

**Full plain-English explainer:** https://patentbrief.org/patent/us/12735424/fused-pyrazine-derivatives-as-a2a-a2b-inhibitors

**Original patent:** https://patents.google.com/patent/US12735424

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._